Panelists discuss how clinically -diagnosed (or functional) Familial Chylomicronemia Syndrome (FCS), involving a bi-allelic genetic defect, differs in diagnostic approach from classical FCS, emphasizing the challenges of diagnosing without genetic confirmation.

Panelists discuss how genetic mutations, such as mutations in the LPL gene, play a critical role in the pathophysiology of Familial Chylomicronemia Syndrome (FCS) by impairing triglyceride metabolism and increasing the risk of severe hypertriglyceridemia.

The panel of experts review the long-term data on the recently FDA-approved PPAR-δ agonist seladelpar for primary biliary cholangitis (PBC), focusing on its efficacy, safety, and impact on liver biochemistry markers over time.

The panel of experts explore the use of FDA-approved peroxisome proliferator-activated receptor (PPAR) agonists in the management of primary biliary cholangitis (PBC), discussing their scientific basis, how they differ from fibrates, and their role in combination with ursodeoxycholic acid (UDCA) or as monotherapy for UDCA-intolerant patients.

Data from SURMOUNT-5, a head-to-head trial, demonstrate tirzepatide offered greater weight loss benefits than semaglutide.

This month in review spotlights FDA news, new clinical trial data, and HCPLive’s coverage of the NASPGHAN 2024 annual meeting and AASLD The Liver Meeting.

Previous ASA guidance recommended holding GLP-1 RAs in the perioperative period, but new 2024 multisociety guidance suggests a risk-based approach.

CDC, NIH, and AMA recommend PEMs to be at a 6th-to-8th-grade reading level, while assessed materials were readable at high school or higher levels.

In this iteration of the Month in Review series, a list of highlighted stories in the allergy and immunology space covered in the month of November is provided.

Anemia in heart failure with preserved ejection fraction was linked to right ventricular dysfunction in an analysis of more than 1000 patients in China.

Intra-Cellular Therapies announced they submitted a supplemental New Drug Application to the FDA for lumateperone (CAPLYTA) as an adjunctive therapy to antidepressants for MDD.

An overview and landing page for future installments from HCPLive's 8th annual This Year in Medicine Series.

CT-P41 had similar rates of bone mineral density increases and adverse events in data presented at the ACR 2024 Convergence.

Dreem 3S is the first sleep wearable with an FDA-authorized Predetermined Change Control Plan.

The November Month in Review features a set of dermatology news coverage highlights, including FDA news and developments in psoriasis.

Vivek Kaul, MD, discusses the sensitivity and accuracy of the stool DNA test, providing relevant data, while also describing the role of blood-based tests in colorectal cancer screening and how they complement or differ from stool-based tests.

The GLEAM trial is currently enrolling patients to receive SC291, with data expected in 2025.

Bob Ross, PA-C, shares expert insights on early PAD detection, updated guidelines, and practical tools to improve vascular health outcomes from CAPP 2024.

Two supplemental Biologics License Applications for guselkumab were submitted to the FDA for treatment of children with plaque psoriasis and active juvenile psoriatic arthritis.

The FDA affirmed the planned NDA content and format for Anaphylm expected in Q1 2025, without requiring additional adult clinical trials before submission.

These topline findings regarding MH004, or tofacitinib etocomil ointment 1.0%, demonstrated efficacy for this twice-daily pan-Jak inhibitor in adolescents and adults with eczema.

As announced by NovelMed on December 2, 2024, the FDA has granted IND clearance for Ruxoprubart to commence an efficacy trial for the treatment of IgAN.

Ustekinumab-kfce is planned for launch in February 2025 according to a previous settlement and license agreement with Janssen.

This portion of the latest Lungcast episode includes a discussion of therapies, triggers, and management of AERD.